Canaccord Adams
http://www.canaccordadams.com/default.htmCanaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, their 225 professionals seek out emerging opportunities in their key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, their experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.
View Older Stories View More Recent Stories
-
Canaccord Adams' Handset Survey Is a Positive For AAPL, Neutral For RIMM and Negative for PALM and NOK
-
Canaccord Adams Reiterates a 'Buy' rating on FuelCell Energy (FCEL)
-
Canaccord Adams Initiates Coverage on SinoHub (SIHI) with a Buy; Currently Undervalued
-
Canaccord Adams Upgrades Open Text (OTEX) to Buy; Raises Estimates & PT
-
Canaccord Adams Downgrades Enbridge (ENB) to Hold
-
Canaccord Adams Downgrades Micromet (MITI) to Hold
-
Canaccord Adams Reiterates a 'Buy' on Mosaic (MOS); Updates EPS Estimates After Business Realignment Announcement
-
'Cash for Clunkers' 3-Months Later: A Boon or a Bust?
-
CF International (ICFI) Files 3.1M Common Offering
-
Canaccord Adams Reiterates a 'Speculative Buy' on Delcath Systems (DCTH); Raises Estimates & PT
-
Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
-
Green Mountain (GMCR) Will Likely Win Diedrich Coffee (DDRX) Bidding War - Analyst
-
Canaccord Adams Raise Target on Yamana Gold (AUY) to $16.50
-
Another Analyst Boosts Google (GOOG) Price Target to $700, This Time UBS
-
Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
-
Oncolytics Biotech (ONCY) Announces Terms of 4.25M Unit Offering
-
Canaccord Adams Initiates Coverage on Momenta Pharmaceuticals (MNTA) with a Buy
-
Canaccord Adams Initiates Coverage on Cytokinetics (CYTK) with a Buy
-
Canaccord Adams Initiates Coverage on XOMA (XOMA) with a Buy; XOMA-052 Promising New Type 2 Diabetes Drug
-
Canaccord Adams downgrades Poniard Pharmaceuticals (PARD) to Hold; Less Attractive Risk/Reward
-
Canaccord Adams Downgrades Poniard Pharmaceuticals (PARD) to Hold
-
Canaccord Adams Initiates Coverage on RINO Int'l (RINO) with a Buy; Well Positioned Technology Leader, Undervalued Relative to Peer Group
-
Canaccord Adams Initiates Coverage on Omeros Corporation (OMER) with a Buy
-
Magnum Hunter Resources (MHR) Closes & Receives Funds on Previously Announced $11.078 Million Offering
-
Delcath Systems (DCTH) Prices 8.5M Share Offering at $3.60/Share
-
Canaccord Starts SWSI, RES, NBR at Buy, PTEN at Hold
-
Canaccord Adams Downgrades Golden Star Resources Ltd. (GSS) to Hold
-
Canaccord Adams Maintains a 'Buy' on Silver Wheaton (SLW); Raises Price Target
-
Canaccord Adams Reiterates a 'Buy' on Veeco Instruments (VECO); Raises PT & Estimates
-
Canaccord Adams Reiterates a 'Buy' on NBTY (NTY); Raises PT
-
Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX)
-
Canaccord Adams Reiterates a 'Buy' on Rosetta Resources (ROSE); Raises PT
-
Canaccord Adams Upgrades Pan American Silver (PAAS) to Buy
-
Daily State of the Markets: The Trade Lives On (For Now)
-
Trius Therapeutics (TSRX) Files $86.25M IPO
-
ICF International (ICFI) Shares Trade Higher on Earnings/Analyst Report
-
Canaccord Adams Maintains 'Buy' on ICF International (ICFI); Raises PT
-
Canaccord Adams Maintains a 'Buy' on Fuel Systems Solutions (FSYS); Raises PT & Estimates
-
Canaccord Adams Reiterates a 'Buy' on EnerNOC (ENOC); Raises PT & Estimates
-
Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
-
Canaccord Adams Reiterates a 'Buy' on HeartWare International (HTWR); Raises PT & Estimates
-
Canaccord Adams Reiterates a 'Buy' on Towerstream Corp. (TWER); Tweaks Estimaets
-
NVIDIA (NVDA) Shines In Q3 (Update)
-
Canaccord Adams Reiterates a 'Buy' on NVIDIA (NVDA); Raises Estimates
-
Canaccord Adams Reiterates a 'Buy' on Perficient (PRFT), Raises PT
-
Canaccord Adams Maintains a 'Hold' on Marchex (MCHX); Raises PT
-
Canaccord Adams Reiterates a 'Buy' on LivePerson (LPSN); Raises PT & Estimates
-
Cisco (CSCO) Delivers The Goods In Q1, Says Recovery Taking Hold (Update)
-
Canaccord Adams Downgrades Dolby Laboratories (DLB) to Hold
-
Canaccord Adams Upgrades Atheros (ATHR) to Buy

